tbuckley/cabot-search huggingface dataset:
FRI0448 Radiological occult sacroiliac abnormalities in asymptomatic patients with inflammatory bowel disease (IBD) might precede the development of spondyloartropathy
Authors: F. Bandinelli, R. Terenzi, L. Giovannini, M. Milla, S. Genise, S. Biagini, V. Annese, M. Matucci Cerinic
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The involvement of sacroiliac joints (SIJ) is one of the major features of Spondyloartropathies (SpA) associated to inflammatory bowel disease (IBD) and it is well known that the early detection of SIJ inflammation is crucial to identify and treat SpA on-time. <h3>Objectives</h3> To investigate X rays sacroiliitis in IBD patients, not presenting signs and symptoms of Spondyloarthropathy (SpA), and the differences of IBD clinical and familial variables between patients with sacroiliac (SIJ) abnormalities and without. To follow up sacroiliitis patients during 3 years, evaluating the onset of SpA inflammatory back pain (IBP). <h3>Methods</h3> 81 patients (55 Crohn-CD- and 26 Ulcerative rettocolitis -UC) with remittent and low active IBD, froma tertiary referral centre of gastroenterology Unit, were studied with X rays of SIJ (postero-anterior and oblique scan) and scored with the New York criteria by two rheumatologists. Differences of IBD clinical variables (CD and UC, remittent and low active bowel disease, durations of symptoms, extra-intestinal involvement, patients treated with surgery and not, ESR and CRP) and familiarity (for psoriasis, IBD, celiac syndrome, SpA), between patients with SIJ X rays findings and without were investigated. At three years of follow up, we re-evaluated patients with radiological sacroiliitis for onset of chronic (&gt;3 months) IBP, belong Berlin definition, and, finally, for ASAS criteria positivity. <h3>Results</h3> 22/81 patients (27,1%) showed X rays sacroiilitis at baseline. New York grade 1 and 2 was observed in 17/22 (77,3%) and 12/22 (54,5%) patients, respectively. X rays sacroiliac involvement did not correlate with IBD clinical and familial variables. All patients were HLA B27 negative. After 3 years of clinical evaluation, 6/22, presented episodic IBP, 1/22 presented only back morning stiffness &gt;30 minutes (&gt;3 months) without pain and 3/22 developed chronic (&gt; 3 months consecutive of duration) with almost two Berlin criteria for IBP. The three patients fulfilling Berlin criteria for chronic IBP, showing SIJ bone oedema at MRI (either with gadolinium either with STIR), underwent to ASAS definition for Spa and met the indication for antiTNF alpha treatment (never assumed before for IBD). <h3>Conclusions</h3> In IBD, occult X rays sacroiliitis in IBD might precede the onset of axial symptoms. At the moment, none clinical feature at baseline might be indentified to define those patients at risk to develop SpA. <h3>Disclosure of Interest</h3> None Declared
Subcutaneously Obstructed Ventriculoperitoneal Shuntogram
Authors: Lorenzo Mannelli, Serena Monti, David Shin, Ivano Lomabardo, Fatemeh Behnia
Journal: Clinical Nuclear Medicine (2014)

A 65-year-old man presented with headache, altered mental status, and somnolence. The patient had a ventriculoperitoneal (VP) shunt revised a month earlier. A CT of the head was performed, which demonstrated interval development of hydrocephalus compared with the prior examination done at the time of the shunt revision. Further evaluation of the VP shunt dynamics was obtained through a radionuclide shuntogram using 99mTcO4. The shuntogram demonstrated passage of the radiotracer down the VP shunt tubing. This case illustrates the utility of radionuclide shuntogram in demonstrating an unusual cause of hydrocephalus after VP shunt placement.
Abstract 1949: Proliferation of cell lines from pancreatic ductal adenocarcinomas and ductal epithelia are stimulated by acute and chronic exposure to nicotine and ethanol via modulation in neurotransmitter production
Authors: Mohammed H. Al-Wadei, Hussein A. Al-Wadei, Hildegard M. Schuller
Journal: Cancer Research (2011)

Abstract Pancreatic cancer is the leading cause of cancer mortality in both men and women in western countries due to its unresponsiveness to available therapeutics. It is well documented that smoking, diabetes and pancreatitis from chronic alcohol consumption are risk factors for this type of cancer. More than 95% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDACs) that arise from pancreatic ductal epithelia. Our lab has previously shown that nicotine stimulates the proliferation and migration of human small airway epithelial cells and the adenocarcinomas derived from them in vitro due to nicotine induced changes in the sensitivity of the nicotinic acetylcholine receptors. Such changes caused an increase in the production and secretion of excitatory neurotransmitters, but decreased the production and secretion of inhibitory neurotransmitter γ-aminobutyric acid (GABA). In analogy to these findings in lung cells, both nicotine and ethanol stimulated cell proliferation in PDAC cell lines Panc-1 and BXPC-3 and in immortalized pancreatic duct epithelial cells HPDE6-C7. Acute and chronic treatment of all cell lines with nicotine or ethanol alone and in combination significantly increased the production of noradrenaline and adrenaline by the cells while significantly reducing GABA production. Western blots are currently underway to assess the potential modulation of nicotinic receptor protein expression as well signaling pathways. Our findings suggest a potential role for these pathways contributing to the development of smoking and alcohol related pancreatic carcinogenesis and may result in the identification of novel targets for the prevention and therapy of this malignancy. Supported by R01CAo42829 with the National Cancer Institute. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1949. doi:10.1158/1538-7445.AM2011-1949
ASSESSMENT OF THE SEVERITY OF LEFT ANTERIOR DESCENDING CORONARY ARTERY STENOSES USING TRANSTHORACIC ENHANCED DOPPLER ECHOCARDIOGRAPHY IN CONVERGENT COLOR DOPPLER MODE: VALIDATION OF A METHOD BASED ON THE CONTINUITY EQUATION
Authors: Carlo Caiati, Mario Lepera, Daniela Santoro, Dario Grande, Fortunato Iacovelli, Nicola Tarantino, Antonio Tito, Isabella Lacitignola, Marco Basile, Filippo Masi, Stefano Favale
Journal: Journal of the American College of Cardiology (2013)
Intramural hematoma: a rare complication of endoscopic injection therapy for bleeding peptic ulcers
Authors: A. Sadio, P. Peixoto, E. Cancela, A. Castanheira, V. Marques, P. Ministro, A. Silva, A. Caldas
Journal: Endoscopy (2011)

Intramural hematomas of the gastrointestinal tract are a rare entity. We report two cases of intramural hematoma that developed following endoscopic therapy for bleeding ulcers.
ATHEROTHROMBOTIC RISK STRATIFICATION AND EZETIMIBE USE IN IMPROVE-IT
Authors: Erin Ann Bohula May, David Morrow, Christopher Cannon, Robert Giugliano, Michael Blazing, Ping He, Sabina Murphy, White Jennifer, Antero Kesaniemi, Terje Pedersen, Adrian J. Brady, Yale B. Mitchel, Andrew Tershakovec, Eugene Braunwald
Journal: Journal of the American College of Cardiology (2016)
P1076 SERUM HEPATITIS B SURFACE ANTIGEN QUANTITATION PREDICTS GENOTYPIC RESISTANCE DURING NUCLEOSIDE ANALOGUES MAINTENANCE THERAPY
Authors: J. Heo, H.Y. Woo, M. Cho, K.T. Yoon, W.Y. Tak, S.Y. Park, W. Lim
Journal: Journal of Hepatology (2014)
Abstract 2923: Glucose-regulated protein 78(GRP78) mediated the therapeutic efficacy of epirubicin via the downregulation of intracellular oxidative stress in colon cancer cells.
Authors: Yu-Jia Chang, Ching-Hsein Chen, Po-Li Wei
Journal: Cancer Research (2013)

Abstract Background: The 78-kDa glucose-regulated protein (GRP78) is induced in the cancer microenvironment and can be considered as a novel predictor of responsiveness to chemotherapy in many cancers. However, there is little information regarding whether the expression level of GRP78 affects epirubicin treatment in colon cancer. Methods: The expression levels of GRP78 were determined in HT-29 and DLD-1 colon cancer cells. GRP78 expression was suppressed in DLD-1 cells using a short interfering RNA (siRNA) technique. The anti-cancer effects of epirubicin were examined using a MTT assay, TUNEL assay, and cell cycle analysis. The status of intracellular reactive oxygen species (ROS) was determined. Results: In this study, we found thateEpirubicin resistance reduced in cells with suppressed GRP78, in contrast to the parental cells, as determined by survival assays. Cell cycle analysis and TUNEL assays revealed that the apoptotic cell population was increased in the GRP78 knockdown cells treated with epirubicin compared to the scrambled control cells. We found that intracellular reactive oxygen species were higher in GRP78 knockdown DLD-1 colon cancer cells compared with scrambled control cells. Treatment with epirubicin in GRP78-knockdown DLD-1 cells enhanced apoptosis and was associated with decreased production of intracellular ROS. Conclusions: In summary, our results indicate that GRP78 expression levels were highly correlated with the therapeutic efficacy to epirubicin which was associated with decreased production of intracellular ROS. Citation Format: Yu-Jia Chang, Ching-Hsein Chen, Po-Li Wei. Glucose-regulated protein 78(GRP78) mediated the therapeutic efficacy of epirubicin via the downregulation of intracellular oxidative stress in colon cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2923. doi:10.1158/1538-7445.AM2013-2923
Cold needle-knife papillotome as rescue dilator for endoscopic ultrasound-guided choledochoduodenostomy
Authors: Jesús García-Cano
Journal: Endoscopy (2014)

Endoscopic ultrasound (EUS)-guided biliary drainage via either gastrohepatostomy or choledochoduodenostomy are accepted and widespread procedures when endoscopic retrograde cholangiopancreatography (ERCP) fails. EUS guidewire insertion through a 19-G needle into a dilated biliary system is usually a straightforward maneuver. The drainage difficulty begins when the enterobiliary tract has to be dilated over the guidewire to allow the passage of the stent [1]. For this purpose, several dilation devices have been described; some of them employ electric current and others take advantage of the small tip of the device. Initial attempts to enlarge the enterobiliary tract with dilation balloons may fail due to a lack of sufficient stiffness in the tip of the balloon catheter or the inability to inflate the balloon in the middle of the tract. Therefore, another more rigid device needs to be employed prior to balloon dilation. In these situations, we have found the use of a cold needle-knife, without exposure of the wire or use of the electric current, to be helpful.
THU0158 The Inflammatory Marker S100A12 is Highly Associated with a Comprehensive 78-Joints Ultrasonographic Synovitis Score in Patients with Rheumatoid Arthritis Treated with Adalimumab
Authors: H. H. Nordal, H. B. Hammer, M. K. Fagerhol, A. K. Halse, R. Jonsson, J. G. Brun
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The serum levels of the pro-inflammatory calcium-binding protein S100A12 (mainly found in neutrophil granulocytes) correlate well with clinical assessments of disease activity of patients with rheumatoid arthritis (RA). Ultrasonography (US) is a sensitive method for assessing disease activity during follow-up of RA patients and has been shown to detect residual inflammation in clinical remission. <h3>Objectives</h3> To explore the validity of S100A12 in serum as a potential inflammatory marker by comparing the levels with the results of a comprehensive US assessment. <h3>Methods</h3> A comprehensive study was performed in 20 RA patients (median (range) age 53 (21-78), disease duration 7.5 (1-26) years, 75 % women) (including clinical (DAS28 and questionnaires), laboratory (SR and CRP) and US examination (B-mode (BM) and power Doppler (PD) of 78 joints, 36 tendons and 2 bursae) at baseline (before starting adalimumab as their first biological drug) and after 1, 3, 6 and 12 months. Serum S100A12 was analysed by a sandwich ELISA. The changes between baseline and follow-up of US scores and laboratory markers were explored by Wilcoxon signed rank test. Spearman's rank correlation was used for analysing the associations between inflammatory markers and US scores. <h3>Results</h3> The patients had median (range) S100A12 levels of 49 (18-475) ng/ml at baseline, 34 (18-687) after 1 month, 23 (16-173) after 3 months, 33 (19-394) after 6 months and 40 (12-620) after 12 months, while for CRP the corresponding results were 4.5 (1-136), 2.0 (1-163), 2.5 (1-26), 2.5 (1-78) and 4.5 (1-86) mg/l and for ESR 20.0 (3-67), 13.0 (3-108), 14.5 (2-65), 14.5 (5-99), 17.5 (3-78) mmHg/h. Significantly decreased levels were found at 3 months for S100A12 (p&lt;0.01), at 3 months for CRP (p&lt;0.01) and at 1 and 3 months (p&lt;0.01) for ESR (figure). Compared with the conventional inflammatory markers CRP and ESR, the neutrophil protein S100A12 had the highest correlations with the comprehensive BM and PD sum scores during the 12 months follow-up, (median (range) coefficients of 0.55 (0.35-0.78) for sum score BM and 0.45 (0.27-0.75) for sum score PD). <h3>Image/graph</h3> <h3>Conclusions</h3> S100A12 was found closer associated to the comprehensive US examinations than conventional inflammatory markers. The US scores reflect the degree of synovitis in RA patients during biologic treatment, and thus the present finding of high associations between US pathology and S100A12 shows that S100A12 is a promising serum biomarker for RA patients. <h3>Disclosure of Interest</h3> None Declared
Abstract 1686: Low dose metronomic gemcitabine has high antimetastatic efficacy in an orthotopic mouse model of pancreatic cancer
Authors: Hop S. Tran Cao, Michael Bouvet, Eric Romney, Sharmeela Kaushal, Alex Keleman, Ginna Kim, John Fruehauf, David K. Imagawa, Robert M. Hoffman, Matthew H.G. Katz
Journal: Cancer Research (2010)

Abstract Therapies for metastasis of pancreatic cancer (PC) are ineffective. We report here the efficacy of metronomic gemcitabine with and without the tyrosine kinase inhibitor sunitinib (SU) on metastasis in an orthotopic model of PC. Mice with highly metastatic, orthotopic PC expressing red fluorescent protein (RFP) were treated with intraperitoneal gemcitabine on a metronomic (1 mg/kg daily, MET) or with maximum tolerated dose (150 mg/kg twice weekly, MTD) schedule with or without oral SU. Primary tumor growth, metastasis, and survival were evaluated. Primary tumor growth and metastasis were quantified by fluorescence imaging. Control mice with orthotopically-implanted MIA-PaCa-2-RFP died of local and widespread metastatic disease within 4 weeks. Gemcitabine at daily doses of 2 mg or greater led to toxicity and death within 1 month in mice without tumors but MET at 1 mg/kg daily was well tolerated. Treatment of mice with orthotopic MIA-PaCa-2-RFP with MET at 1 mg/kg daily for 2 weeks dramatically suppressed metastasis at multiple sites_an effect enhanced by SU (p&amp;lt;0.05). Although primary tumor growth was inhibited by MET+SU (p&amp;lt;0.05), it was not inhibited by either MET or SU alone. Both MET and SU had a modest effect on survival compared to control but survival was limited by extensive primary tumor growth. MET+SU had a more pronounced effect on survival (p&amp;lt;0.05). MTD with or without SU had the most pronounced effects on primary tumor growth and survival but its antimetastatic effect was similar to that of MET+SU (p&amp;lt;0.05). Antimetastatic activity approaching that of standard MTD gemcitabine was achieved with a gemcitabine dose reduced 42 times from MTD using MET and was further enhanced by sunitinib. Our results suggest the clinical potential of this well-tolerated regimen of MET against PC in the adjuvant and maintenance settings. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1686.
Abstract 2830: Multikinase inhibition by TG02 is therapeutically effective in two forms of breast cancer
Authors: M Jesús Ortiz-Ruiz, Francis J. Burrows, M Florencia Ré-Louhau, Alberto Ocaña, Atanasio Pandiella, Azucena Esparís-Ogando
Journal: Cancer Research (2012)

Abstract Breast cancer (BC) is a heterogeneous disease in which several distinct genetic and histopathological types have been defined. Triple-negative breast cancer (TNBC) lacking ER/PR and HER-2 is the most aggressive and untreatable form. In the case of HER2+ tumors, and despite the emergence of trastuzumab and lapatinib, in the metastatic setting these tumors remain incurable due to the innate or acquired drug resistance. A number of kinases are implicated in the proliferation and survival of breast cancer cells. Here, we characterize the antitumor activity of the multikinase inhibitor TG02 in TNBC and HER2+ BC. TG02 is a novel drug with a unique kinase inhibitory spectrum, targeting both the cell cycle regulatory CDKs 1/2 and the transcriptional regulators CDKs 7/9, along with the emerging oncogenic MAPK ERK5 and the DNA damage response mediator CDK5, all within a narrow low nanomolar potency range. In panels of breast cancer cell lines, TG02 was potently and consistently antiproliferative at low (100nM) and proapoptotic at moderate (250-1000nM), clinically-achievable concentrations. In TNBC cells, the drug usually induced a G2/M arrest, whereas blockade of cell cycle progression at the G1/S boundary was more common in HER2+ lines. Simultaneous multikinase inhibition was demonstrated in several cellular models, showing that cell cycle arrest induced by inhibition of CDK1 and CDK2 progresses to apoptosis associated with profound depletion of the short-lived survival proteins of the Bcl-2 and IAP families downstream of CDK9-dependent loss of RNA polymerase II-driven transcription. TG02 was synergistic in combination with chemotherapy in TNBC models in vitro and in vivo and with trastuzumab and lapatinib in HER2-overexpressing cell lines. A majority of TNBC and HER2+ lines expressed constitutively active ERK5, which was efficiently inhibited by TG02 and may contribute to the antitumor activity of the drug. A robust DNA damage response including CHK1/2 activation and formation of H2AX foci was induced in TNBC cells, presumably due to inhibition of CDK5 by TG02, so we will also report on the mechanism-based combination of TG02 with PARP inhibitors in this setting. These data support clinical development of this compound for the treatment of TNBC and HER2+ BC, especially in combination with standard of care treatments used in these breast neoplasias. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2830. doi:1538-7445.AM2012-2830
TCT-65 Clinical impact of IVUS-guided left main PCI: insights from the multicenter study ESTROFA-LM
Authors: Jose De la Torre Hernandez, Fernando Alfonso, Angel Sanchez Recalde, Manuel Jimenez Navarro, Armando Pérez de Prado, Hernandez Felipe, Omar Abdul-Jawad Altisent, Neus Salvatella, Jaime Elizaga, Fernando Rivero-Crespo, Federico Gimeno, Ramon Calviño, Jose Moreu, Francisco Bosa, Jose Rumoroso, Juan Bullones, Jose Fernandez Diaz, Jose Ruiz Arroyo, Victor Aragon, Arsenio Gallardo, Monica Masotti
Journal: Journal of the American College of Cardiology (2012)
Abstract LB-14: High-risk cervical human papillomavirus infections among human immunodeficiency virus-positive women in the Bahamas.
Authors: Elizabeth Blackman, Dionne N. Dames, Raleigh Butler, Emanuela Taioli, Stacy Eckstein, Karthik Devarajan, Andrea Griffith-Bowe, Perry Gomez, Camille Ragin
Journal: Cancer Research (2013)

Abstract Background: It has been demonstrated in immunocompromised females that HR HPV genotypes other than 16 and 18 have been detected in a significant proportion of these individuals. We aim to evaluate the frequency of HR HPV genotypes in a population of HIV-positive Caribbean women, detect characteristics associated with HR HPV infections other than HPV16 and 18, and investigate the clustering of HPV genotypes in this population. Methods: One hundred and seventy-six non-pregnant, HIV-positive females ≥18 years were recruited. Each participant received a vaginal examination and completed a questionnaire. Results: Mean age was 38.7 years for women positive for HR HPV and 44.4 years for women negative for HR HPV (P value = 0.0018). The majority of the HR HPV-positive women were on HAART for 2-4 years. Non-negative matrix factorization identified HPV 16, 18, 52 and 58 as the most influential HPV high-risk types. Among the women who were HIV+ for more than 2 years, secondary CART analysis revealed those aged ≤29 had statistically significant different cervical abnormality profile compared to women &amp;gt;29 years; specifically, younger women were more likely to have dysplasia, while older women had normal cervical cytology. Also, the mean number of years on HAART for ≤29 years old was only 1 year (std dev. ±1.3) while those &amp;gt;29 years old the mean was 3.6 years (std. dev. ± 2.5) (p = 0.009). Conclusions: HR HPV in the immunocompromised female consists of more than just HPV 16 and 18, but also types HPV 52 and 58, which are likely to influence the course of HPV infections and the development of cervical cytological abnormalities. Targeted interventions to boost treatment compliance among HIV- positive women are needed to reduce the risk of cervical abnormalities. Citation Format: Elizabeth Blackman, Dionne N. Dames, Raleigh Butler, Emanuela Taioli, Stacy Eckstein, Karthik Devarajan, Andrea Griffith-Bowe, Perry Gomez, Camille Ragin. High-risk cervical human papillomavirus infections among human immunodeficiency virus-positive women in the Bahamas. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-14. doi:10.1158/1538-7445.AM2013-LB-14